Global Myasthenia Gravis Drugs Market to Exhibit 13% CAGR 2017-2021 as Disease Prevalence Rises


Published Date : Mar 29, 2017

Albany, New York, March 29, 2017: A recent report added to the vast research report portfolio of MarketResearchReports.biz presents a detailed overview of the growth prospects of the global market for myasthenia gravis drugs over the period between 2017 and 2021. The report, titled “Global Myasthenia Gravis Drugs Market 2017-2021,” states that the market will exhibit an impressive 13% CAGR over the said period. The key driving force will be the encouraging pace of developments across novel drug categories such as monoclonal antibodies. 

A key trend observed in the market over the past few years is the constant rise in the number of strategic acquisitions observed in the global market. Several key vendors in the market are pursuing inorganic growth strategies such as strategic collaborations and acquisitions as a way of expanding their geographical presence and product portfolios. An instance is the June 2016, US$5.9 bn acquisition of Dyax Corp. by Shire. Such acquisitions are expected to further improve the rate of development of the global market for myasthenia gravis drugs in the next few years.

On the basis of therapy area, the market for myasthenia gravis drugs has been segmented into immunosuppressants, anticholinesterases, and intravenous immune globulins. Of these, the segment of anticholinesterases therapy was one of the most-prominent therapy segments in terms of rate of growth in 2016. The segment is expected to retain its rate of growth over the next few years as well. 

From a geographical perspective, the global market for myasthenia gravis drugs has been segmented in the report into Americas (North America and South America), APAC (Asia Pacific), and EMEA (Europe, Middle East and Africa). Of these, the Americas emerged as the leading contributor of revenue to the global market in 2016 and is expected to retain dominance over the report's forecast period as well. The high rate of incidence of the diseases is the prime factor driving the market in the region. 

For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/938642 

Moreover, as the disease remains largely undiagnosed, its prevalence should be higher than is presently estimated, presenting the increased need for effective drugs to treat it. This has compelled companies to increase their efforts in understanding the etiology of the disease in a better way and formulating effective drug candidates to treat it. 

The myasthenia gravis drugs market features an intensely competitive vendor landscape as key vendors face stiff competition from companies manufacturing off-label drugs. The rise in R&D activities and strategic consolidations, mergers, and acquisitions are expected to further intensify competition in the market. 

Some of the leading companies operating in the market are Pfizer, Grifols, Shire, Flamel Technologies, Valeant Pharmaceuticals, F. Hoffmann-La Roche, Galencia, Cytokinetics, Alexion Pharmaceuticals, Catalyst Pharmaceuticals, GlaxoSmithKline, Curavac, Mitsubishi Tanabe Pharma, Lupin Pharmaceuticals, CSL, and Novartis.

To order report Call Toll Free: 866-997-4948 or send an email on sales@marketresearchreports.biz